WEGOVY® FLEXTOUCH® 0.25mg (Italian)

WEGOVY® FLEXTOUCH® 0.25mg is the initiation dose of semaglutide, used as part of a dose-escalation regimen for weight management in adults with obesity or overweight and at least one weight-related comorbidity. It belongs to the GLP-1 receptor agonist class and mimics the action of the human glucagon-like peptide-1, regulating appetite and reducing food intake.

This once-weekly subcutaneous injection is not intended for long-term use at 0.25mg, but rather to help the body acclimate to semaglutide, minimizing gastrointestinal side effects before moving to higher therapeutic doses. It is delivered in a pre-filled FlexTouch® pen, ready for self-administration.

WEGOVY® 0.25mg is intended to be administered once weekly, on the same day each week, preferably at any time of the day, with or without meals. The dose is fixed at 0.25mg for the first 4 weeks, after which patients escalate to higher doses.

• Dose: 0.25 mg semaglutide per 0.5 mL

• Frequency: Once weekly

• Route: Subcutaneous injection (abdomen, thigh, or upper arm)

• Device: FlexTouch® pre-filled pen

• Needle included: Yes

• Duration at this dose: 4 weeks before up-titration

WEGOVY® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a BMI ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia.

Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)

• Multiple endocrine neoplasia syndrome type 2 (MEN 2)

• Hypersensitivity to semaglutide or any excipient

• Not recommended in pregnancy or breastfeeding

Side Effects:

• Very common: Nausea, vomiting, diarrhea, constipation

• Common: Abdominal pain, headache, fatigue, decreased appetite

• Rare: Pancreatitis, gallbladder issues

• Serious risks: Thyroid C-cell tumors (in animal studies), renal events in context of dehydration

WEGOVY® contains semaglutide, a GLP-1 receptor agonist that is long-acting and structurally modified for stability and sustained action. Each 0.5 mL injection delivers 0.25 mg of semaglutide.

• Active substance: Semaglutide 0.25 mg

• Excipients:

  • Disodium phosphate dihydrate

  • Sodium chloride

  • Hydrochloric acid/sodium hydroxide (pH adjustment)

  • Water for injections

• Formulation: Clear, colorless or slightly yellow solution

Each carton of WEGOVY® 0.25mg includes four single-dose pens, each prefilled and ready to use, covering one month of therapy.

• 4 pre-filled pens, each with 0.5 mL delivering 0.25 mg semaglutide

• 4 NovoFine® Plus needles (32G, 4mm)

• Instructions for use leaflet

• Pen is pre-assembled, no priming required

While most side effects are mild to moderate, particularly during initiation, some gastrointestinal effects can be persistent. The 0.25 mg dose is primarily used to reduce side effects during treatment initiation.

• Common: Nausea (up to 44%), vomiting, diarrhea, constipation

• Less common: Fatigue, dyspepsia, bloating, dizziness

• Rare: Cholelithiasis, acute pancreatitis

• Serious: Risk of thyroid tumors (animal data), kidney impairment due to dehydration

Proper storage is critical to maintaining the product’s efficacy. The pens are temperature-sensitive and must be protected from freezing and heat.

• Unopened pens: Store in a refrigerator (2°C–8°C)

• In-use pens: Can be kept at room temperature (up to 30°C) for 6 weeks

• Do not freeze

• Protect from direct light

• Discard if frozen or past expiration